Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

ressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotec
'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tough, ultralight foam of atom-thick sheets can be made ... invented at Rice University. , In microscopic images, ... with floors and walls that reinforce each other. The ... and walls of graphene oxide that self-assemble with the ... researchers say the foam could find use in structural ...
(Date:7/29/2014)... July 29, 2014  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: IPXL).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On July 29, 2014, Impax Laboratories, Inc. (the "Company") ...
(Date:7/29/2014)...  Discovery Laboratories, Inc. (Nasdaq: DSCO),  a specialty ... of respiratory critical care, will report its second quarter ... the open of the U.S. financial markets.  ... teleconference and webcast at 9:00 a.m. Eastern Time that ... management will discuss the 2014 second quarter financial ...
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
Breaking Biology Technology:Tough foam from tiny sheets 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... DNA-Based Test Produces Decisive Result Within Minutes, ... Enigma Diagnostics,the life sciences company developing rapid ... has successfully completed a project,commissioned by the ... a rapid, point-of-care diagnostic system for screening ...
... Nov. 8 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... 30, 2007. Net loss for the quarter and nine ... or $0.26 per share and $0.46 per share,compared to a ... and,$0.76 per share, in the same periods last year. ...
... The Organizations Advocating Use of Hand ... Prevention and Protection, NORCROSS, Ga., Nov. 8 ... and the media continue,to report daily on recent school ... to this drug-resistant staph infection*. Even though,hand-washing is advocated ...
Cached Biology Technology:Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 2Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 3Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3
(Date:7/28/2014)... PORTLAND, Ore. The findings of a new study suggest ... pills may not work as well in obese women, compared ... control pills are a one-size-fits-all method, researchers say, but as ... how well the pill works for obese women. Studies have ... levels in the body, which may in turn affect how ...
(Date:7/28/2014)... Kansas He calls himself the bug hunter, but ... can only be found and identified with special methods ... the Kansas State Veterinary Diagnostic Laboratory at Kansas State ... discoveries, porcine enterovirus G, which is an important find ... virus in cells, but didn,t know what it was," ...
(Date:7/28/2014)... HOUSTON (July 28, 2014) Rice University researchers ... chains of varying flexibility that can be used as ... visual proof that "bead-spring" polymers, introduced as theory in ... flexible as required and should be of interest to ... , The work led by Rice chemical and biomolecular ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Seeing is bead-lieving 2
... More than 2,000 former football players are suing the National ... to deal with injuries related to concussions more seriously. ... warrants criticism, the NFL isn,t the only player deserving a ... law expert David Orentlicher, who teaches at Indiana University Robert ...
... , Fraunhofer researchers are exhibiting how renewable, biodegradable ... interior design and the packaging industry at this year,s ... 27 (Hall 5.2a, Booth 103). They consist of ... and diatomaceous earth, a material that is procured from ...
... University of Toronto Scarborough researchers gives the best description ... mental illness called Borderline Personality Disorder (BPD), and could ... shows that brain regions that process negative emotions (for ... BPD, while brain regions that would normally help damp ...
Cached Biology News:Fraunhofer shows bio-tiles and heat-resistant biopolymers 2New insights into the 'borderline personality' brain 2
... The PRO S-7 stirrers ... Spill-resistant housing channels fluids away ... panel features easy-to-use controls which ... 7"x7" ceramic tops feature ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
... PYREX trypsinizing flasks are used ... into cell suspensions by digestion ... neck accepts cotton plugs. Four ... • Height of Baffles mm ...
... The kit for stabilizing 50g of purified RNA ... Plus Kit delivers all of the advantages and ... in addition the RNA can be used for ... This product has been optimised for the stabilization ...
Biology Products: